AGY.LSE Allergy Therapeutics

Healthcare Pharmaceuticals London Exchange
0.0145 GBX
Close of Nov 3, 2026
1.10 12.10
Market cap
GBX 91.8M
P/E
-
P/B
52.16x
ROE
-1,875.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Dec 2025.

Is AGY.LSE undervalued?

Graham number

The Graham number of Allergy Therapeutics cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Allergy Therapeutics fundamental analysis

No fundamental analysis for Allergy Therapeutics yet.

Allergy Therapeutics stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venom…

Full company profile